IFGL Refractories Limited (NSE:IFGLEXPOR)

Ligand Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	605.19	696.51	568.01	1,190	1,476
Short-Term Investments	-	-	40	-	70.5	423
Trading Asset Securities	-	940.03	1,152	1,130	1,155	1,216
Cash & Short-Term Investments	1,545	1,545	1,888	1,698	2,416	3,115
Cash Growth	-16.39%	-18.16%	11.22%	-29.72%	-22.46%	54.32%
Accounts Receivable	-	3,594	3,250	3,498	2,720	2,282
Other Receivables	-	16.18	8.22	8.97	75.68	21.75
Receivables	-	3,610	3,259	3,507	2,801	2,304
Inventory	-	4,047	3,007	3,020	2,594	1,678
Prepaid Expenses	-	69.56	52.49	26.46	46.63	25.03
Other Current Assets	-	239.36	175.07	109.32	194.09	152.5
Total Current Assets	-	9,511	8,382	8,361	8,052	7,275
Property, Plant & Equipment	-	4,518	4,299	3,277	2,271	1,900
Long-Term Investments	-	112.81	112.83	233.88	193.45	94.36
Goodwill	-	1,533	1,738	1,978	2,173	2,454
Other Intangible Assets	-	152.97	171.17	203.34	24.76	22.13
Other Long-Term Assets	-	356.63	200.93	206.49	146.77	93.58
Total Assets	-	16,185	14,904	14,259	12,861	11,839
Accounts Payable	-	2,358	1,793	1,862	1,872	1,551
Accrued Expenses	-	136.4	117.31	76.12	113.19	106.97
Short-Term Debt	-	1,395	798.82	923.01	752.88	363.68
Current Portion of Long-Term Debt	-	158.73	244.15	65.94	31.41	32.64
Current Portion of Leases	-	13.63	13.18	12.1	18.2	22.12
Current Income Taxes Payable	-	16.72	100.44	15.94	18.3	19.71
Other Current Liabilities	-	84.93	63.53	135.32	48.11	161.7
Total Current Liabilities	-	4,164	3,130	3,090	2,854	2,258
Long-Term Debt	-	469.37	586.78	495.95	86.59	119.37
Long-Term Leases	-	95.62	98.02	104.43	101.45	99.18
Long-Term Deferred Tax Liabilities	-	385.76	368.33	518.18	478.22	457.97
Total Liabilities	-	5,115	4,183	4,209	3,521	2,934
Common Stock	-	360.39	360.39	360.39	360.39	360.39
Additional Paid-In Capital	-	3,975	3,975	3,975	3,975	3,975
Retained Earnings	-	5,528	5,355	4,610	4,252	3,838
Comprehensive Income & Other	-	1,207	1,030	1,105	752.68	731.87
Total Common Equity	11,070	11,070	10,721	10,050	9,340	8,905
Shareholders' Equity	11,070	11,070	10,721	10,050	9,340	8,905
Total Liabilities & Equity	-	16,185	14,904	14,259	12,861	11,839
Total Debt	2,133	2,133	1,741	1,601	990.52	636.98
Net Cash (Debt)	-587.49	-587.49	147.16	96.17	1,425	2,478
Net Cash Growth	-	-	53.02%	-93.25%	-42.50%	80.63%
Net Cash Per Share	-8.15	-8.15	2.04	1.33	19.77	34.38
Filing Date Shares Outstanding	72.07	72.08	72.08	72.08	72.08	72.08
Total Common Shares Outstanding	72.07	72.08	72.08	72.08	72.08	72.08
Working Capital	-	5,347	5,252	5,271	5,197	5,017
Book Value Per Share	153.58	153.58	148.73	139.44	129.58	123.54
Tangible Book Value	9,384	9,384	8,812	7,869	7,143	6,429
Tangible Book Value Per Share	130.19	130.19	122.25	109.18	99.10	89.19
Land	-	242.91	236.65	233.17	175.85	175
Buildings	-	2,000	1,563	1,405	1,070	864.56
Machinery	-	5,164	4,196	3,663	2,973	2,675
Construction In Progress	-	273.28	1,041	456.15	250.44	220.74
Leasehold Improvements	-	4.89	4.89	4.89	4.89	4.89

Updated Feb 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.